{
  "ticker": "LLY",
  "timestamp": "2025-12-01T10:00:41.294258",
  "analysis_date": "2024-08-21",
  "historical_mode": true,
  "portfolio_value": 100000.0,
  "verdict": "REJECT",
  "final_position_pct": 0,
  "final_position_dollars": 0.0,
  "confidence": "HIGH",
  "reasoning": "Given the current overbought technical indicators and high valuation metrics, we are decisively rejecting the opportunity to invest in Eli Lilly (LLY). The substantial debt levels further heighten the risk profile, indicating potential limitations on future growth and increased susceptibility to market corrections. Our prudent approach to risk management necessitates a cautious stance in this environment.",
  "key_factors": [
    "Overbought technical indicators",
    "High valuation metrics",
    "Substantial debt levels"
  ],
  "conditions": [
    "Market correction risks",
    "Limited growth potential"
  ],
  "stop_loss_pct": 15,
  "profit_targets": [
    12.5,
    18.8,
    25
  ],
  "guardrail_corrections": [],
  "is_llm_decision": true,
  "risk_controls": {
    "stop_loss": {
      "percentage": 15,
      "dollar_amount": 0.0
    },
    "take_profit": {
      "targets": [
        12.5,
        18.8,
        25
      ],
      "scale_out": [
        0.33,
        0.33,
        0.34
      ]
    },
    "time_limit": {
      "max_holding_period": "90 days",
      "review_frequency": "weekly"
    }
  },
  "risk_consensus": {
    "stances": {
      "aggressive": "AVOID",
      "neutral": "AVOID",
      "conservative": "AVOID"
    },
    "position_sizes": {
      "aggressive": 0.0,
      "neutral": 0,
      "conservative": 0
    },
    "agreements": [
      "All evaluators recommend avoiding"
    ],
    "conflicts": [],
    "avg_position_size": 0.0,
    "red_flags": [
      {
        "flag": "Analysis failed",
        "severity": "HIGH",
        "source": "System"
      }
    ]
  },
  "position_sizing": {
    "range_min_pct": 0.0,
    "range_max_pct": 0.0,
    "final_pct": 0,
    "final_dollars": 0.0
  },
  "agent_votes": {
    "bullish": 0,
    "bearish": 3,
    "neutral": 1,
    "consensus": "STRONG_BEARISH"
  },
  "research_recommendation": "HOLD",
  "report": "\n======================================================================\nRISK MANAGER FINAL DECISION: LLY\n======================================================================\n**Analysis Date:** 2024-08-21 (HISTORICAL)\n**Portfolio:** $100,000\n\n## VERDICT: REJECT\n**Position:** No position taken\n**Confidence:** HIGH\n\n## REASONING\nGiven the current overbought technical indicators and high valuation metrics, we are decisively rejecting the opportunity to invest in Eli Lilly (LLY). The substantial debt levels further heighten the risk profile, indicating potential limitations on future growth and increased susceptibility to market corrections. Our prudent approach to risk management necessitates a cautious stance in this environment.\n\n## KEY FACTORS\n\u2022 Overbought technical indicators\n\u2022 High valuation metrics\n\u2022 Substantial debt levels\n\n## EVALUATOR SUMMARY\n- Aggressive: AVOID @ 0.0%\n- Neutral: AVOID @ 0%\n- Conservative: AVOID @ 0%\n\n## AGENT CONSENSUS\n- Bullish Votes: 0/4\n- Bearish Votes: 3/4\n- Neutral Votes: 1/4\n- Overall: Strong Bearish\n\n## POSITION SIZING\n- Range: 0.0% - 0.0%\n- Final: 0.00% ($0.00)\n\n## RISK CONTROLS\n- Stop Loss: -15%\n- Profit Targets: +12.5%, +18.8%, +25%\n\n## CONDITIONS\n\u2022 Market correction risks\n\u2022 Limited growth potential\n\n======================================================================\n"
}